39. Toxic epidermal necrolysis Clinical trials / Disease details

Clinical trials : 13 / Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	March 15, 2022	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States
2	JPRN-jRCTs031210325	01/10/2021	17/09/2021	Etanercept therapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases of refractory to systemic steroid therapy	open-label, multicenter, single-arm study to evaluate the efficacy and safety of etanercept in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis who were ineffective with systemic steroid therapy	stevens-johnson syndrome, toxic epidermal necrosis stevens-johnson syndrome, toxic epidermal necrosis	Etanercept 50 mg / day is subcutaneously administered on the first day (Day 1). If epithelialization is not complete, administer once on day 8 (Day 8) and day 15 (Day 15) as needed.	Abe Riichirou	NULL	Recruiting	>= 20age old	Not applicable	Both	10	Phase 2	Japan